Arcturus Therapeutics Holdings Inc.

ARCT · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders8.0%

Institutions83.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2013-12-31	2013-12-31	2013-12-31	2012-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$82.03M	$152.31M	$206.00M	$12.36M	$9.54M	$20.79M	$7.16M	$55.89M	$125.35M	$35.74M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$76.26M	-$95.67M	$12.18M	-$202.85M	-$71.52M	-$25.51M	-$1.81M	-$11.38M	-$6.99M	-$1.47M
Operating income as a percentage of revenue.	-93.0%	-62.8%	5.9%	-1641.3%	-749.8%	-122.7%	-25.3%	-20.4%	-5.6%	-4.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$65.78M	-$80.94M	$9.35M	-$203.67M	-$72.15M	-$25.99M	-$4.70M	-$32000	$58000	-$2000
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-3.00	$0.00	$-7.74	$-3.55	$-2.00	$-1.46	$-0.26	$-0.15	$-0.43
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-3.00	$0.00	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2013-12-31	2013-12-31	2013-12-31	2012-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$230.91M	$237.03M	$391.88M	$370.49M	$462.89M	$71.35M	$13.29M	$233.38M	$103.45M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$271.15M	$344.07M	$450.39M	$392.81M	$476.46M	$82.14M	–	–	–	–
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$60.66M	$63.11M	$13.85M	$14.99M	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$57.16M	$103.09M	$180.07M	$164.60M	$79.90M	$56.35M	–	–	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$213.99M	$240.98M	$270.31M	$228.21M	$396.55M	$25.79M	–	–	–	–

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2013-12-31	2013-12-31	2013-12-31	2012-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$74.27M	-$59.75M	$31.99M	-$135.04M	-$42.86M	-$6.45M	-$786000	$9.43M	$53.01M	$7.79M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$230000	$648000	$7.73M	$3.41M	$1.74M	$818000	$165000	$12.09M	$707000	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$74.50M	-$60.40M	$24.27M	-$138.45M	-$44.60M	-$7.26M	-$951000	-$2.66M	$52.30M	–

	You	Peer avg
P/E	–	18.7
Revenue Growth	-89.5%	+81.0%
ROE	-46.3%	-48.3%

Arcturus Therapeutics Holdings Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison